Cookies on this website

We use cookies to improve your experience of our website. You can find out more or opt-out from some cookies.

Skip to content

BETA This is a new service – your feedback will help us to improve it.

Healthcare Improvement Scotland
  • Clinical guidance for professionals
  • Improving care
  • Inspections, reviews and regulation
  • Work with us
  • News and publications
    1. Home
    2. Process guidance
    3. NCMAG advice
    4. NCMAG107 Dabrafenib plus trametinib advice document: October 2023

    Back to   Home

    NCMAG107 Dabrafenib plus trametinib advice document: October 2023

    Posted on: 26 October 2023


    Document Type

    NCMAG advice

    Process guidance

    Summary

    Treatment of patients with locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation and with no satisfactory locoregional treatment options. (Off-label use)

    Decision: supported


    Documents

    NCMAG107 Dabrafenib plus trametinib advice document: October 2023

    PDF, 1MB

    Posted in NCMAG advice, Process guidance

    • Facebook
    • YouTube
    • LinkedIn
    • X
    • Our blog
    • Our podcasts
    • About us
    • Contact us

    Policy links

    • How we use cookies
    • Our privacy policy
    • Accessibility statement
    • Copyright information
    • Complaints and feedback

    © Copyright, Healthcare Improvement Scotland 2025